Phase 3 N=48 Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
PAIN
Primary: NRS Pain Score AUC (NRS*hr) - 1st 24 Hours — 70.4; 59.6; 73.4 Area (NRS*hr) — p=0.4742
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=592 Prevention of Recurrence of Diverticulitis
Diverticulitis
Primary: Percent of Subjects Without Recurrence of Diverticulitis — 62.8; 59.2; 69.1; 67.6 percentage of subjects — p=0.778
Phase 3 N=222 Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26) — 44.1; 11.4 Percentage — p=<.0001
Phase 3 N=149 A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Adverse Events — 98; 10; 16 participants
Phase 3 N=72 Impact of Diabetes on Left Ventricular Remodeling
Diabetes
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA) — 73.03; 78.06; 78.52; 79.03 ml/m^2
Phase 3 N=181 A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Exercise Endurance Time (ET) — 129.45; 13.01 Seconds — p=0.0042
Phase 3 N=128 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis
Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18 — 45.3; 29.5 percentage of participants
Phase 3 N=158 Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Ankylosing Spondylitis · Axial Spondyloarthritis
Primary: Number of Participants Achieving the Assessment in Ankylosing Spondylitis (ASAS) Partial Remission Criteria at Week 28 — 65; 18; 40; 33 Participants
Phase 3 N=86 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
Familial Amyloid Polyneuropathy · ATTR-PN
Primary: Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 — 62.2; 68.8 percentage of participants
Phase 3 N=295 Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
Parkinson Disease
Primary: Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase (Comprised of the Open-label…
Phase 3 N=350 Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: ACR 20 Response Rate at Visit 4 — 108; 34 participants — p=0.0010
Phase 3 N=211 A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events Leading to Discontinuation — 29 participant
Phase 3 N=870 Study to Evaluate the Safety and Efficacy of Denosumab and Actonel® in Post Menopausal Women Transitioned From Alendronate Therapy
Osteoporosis
Primary: Total Hip BMD Percent Change From Baseline at Month 12 — 0.5; 2.0 Percent Change From Baseline — p=<0.0001
Phase 3 N=207 Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
Epilepsy; Paediatric Partial Onset Seizures
Primary: Percentage of Participants With a Decrease From Baseline in 28-day Seizure Frequency of =50%(Responder) in the Maintenance Period(LOCF) — 31; 50 Percentage of Participants
Phase 3 N=36 Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Diabetes Mellitus · Postprandial Lipemia
Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L